AA
BLTE

ALPS Advisors’s Belite Bio BLTE Stock Holding History

ALPS Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,786
Closed -$458K – 1004
2023
Q1 		$458K Sell
15,786
-301
-2% -$9.15K ﹤0.01% 597
2022
Q4 		$492K Buy
+16,087
New +$474K ﹤0.01% 594

Other funds holding BLTE

AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ALPS Advisors's BLTE Position: Q2 2023 in Review

ALPS Advisors sold out of Belite Bio (BLTE) in Q2 2023, closing a stake of 15,786 shares — an estimated $458K sold.

ALPS Advisors first reported a position in BLTE in Q4 2022 and held it in 2 quarters. The position peaked at $492K in Q4 2022. 6 funds tracked by Wall St. Rank hold BLTE as of Q2 2023.

  • ALPS Advisors reported no remaining Belite Bio position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 15,786 Belite Bio shares in Q2 2023, an estimated $458K.
  • ALPS Advisors first reported a position in Belite Bio in Q4 2022 and held it in 2 quarters.
  • ALPS Advisors's Belite Bio position peaked at $492K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Belite Bio as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.